| 1913 |
Mochida established by Ryokichi Mochida,and started production and marketing of
Luestin (antiluetic) and Ogoko (ophthalmic ointment) |
 |
| 1918 |
Renamed as Mochida Pharmaceutical Company |
| 1930 |
Pelanin (first estrogen preparation developed in Japan) |
| 1945 |
Company incorporated |
| 1951 |
Released Sprase (first hyaluronidase preparation developed in Japan) |
| 1954 |
Began overseas marketing with exports to Taiwan |
| 1956 |
Thrombin Mochida (hemostatic enzyme) |
| 1957 |
Built a research laboratory at Oji Plant |
| 1959 |
Transferred focus of sales strategy to obstetrics and gynecology |
| 1962 |
Established the Immunology Division |
| 1963 |
Listed on the Second Section of the Tokyo Stock Exchange (TSE) |
| 1964 |
Nobuo Mochida appointed president |
| Gonavis (Japan's first immunological pregnancy test kit); Kimotab
(anti-inflammatory) |
 |
| 1967 |
Completed Research Laboratory in Oji |
| 1970 |
Established the Paramedical Division |
| Gonavislide (pregnancy test kit); Uronase (fibrinolytic); Skina Babe (baby bath oil) |
| 1972 |
Established the Medical Electronics and Equipment Division |
| Completed the Shizuoka Plant |
| 1975 |
Listed on the First Section of the TSE |
| 1976 |
Completed new headquarters office building at Yotsuya |
| 1978 |
Received a Noteworthy Invention Testimonial from the Science and Technology Agency for the Medilaser balance-type surgical laser head |
| 1979 |
Rocornal |
| 1980 |
Developed monoclonal antibody technology for an immunodiagnostic test Medilaser-S |
| 1981 |
Signed an agreement with Hayashibara Biochemical Laboratory,Inc., for joint research of interferon α |
| 1982 |
Completed the Fuji Central Research Laboratory |
| 1983 |
Established the Mochida Memorial Foundation for Medical and Pharmaceutical Research |
| 1984 |
Nobuo Mochida awarded the Medal with Purple Ribbon for research on the first surgical laser unit developed in Japan |
| Arasena-A |
| 1985 |
Ei Mochida appointed president |
| Miraclid |
 |
| 1986 |
Florid®-F injection; Grandaxin |
| 1987 |
Ei Mochida awarded the Medal with Purple Ribbon for R&D activities on an immunochemical diagnostic reagent |
| 1988 |
Signed an agreement with Taisho Pharmaceutical Co.,Ltd., allowing that company to market Dermarin, an OTC drug for treating dermatomycosis |
| Collage Soap series; Isoprinosine; IFN α Mochida 500; IFN β Mochida; Diode-laser therapy unit |
| 1989 |
Finalized agreements with Upjohn Co., for developing and marketing their prostaglandin derivative; with Dojindo Laboratories to develop diagnostic reagents based on FIA |
| Tecipul |
| 1990 |
Susumu Watanabe appointed president |
| Concluded marketing agreement with Matsushita Electric Industrial Co.,Ltd., for the Medilaser-10S fiber-optic carbon dioxide surgical laser unit |
| Epadel Capsule 300; |
 |
| 1991 |
Commenced operations at the Otawara Plant |
| Concluded agreement of an antimycotic agent with Imperial Chemical Industries,PLC |
| Mammotec |
| 1992 |
Signed agreements with Ostex International,Inc., for the commercialization and marketing of Osteomark®; with Yokogawa-Hewlett-Packard,Ltd., to market an obstetric care unit |
| Medilaser-30S; Arasena-A Ointment; Thrombin Oral Fine Granules; Bathquina |
| Commenced J-MIC (EBM study for Rocornal) |
| 1993 |
Florid® Oral Gel; Sonotec-IV; Collage Liquid Soap |
| 1994 |
Additional indication for Epadel(for hyperlipidemia) approved; Miraclid liquid formulation for injection; Sonovista-EX; Medilaser Soft150 |
| 1995 |
Signed agreements with Smithkline Beecham Seiyaku K.K. for the co-marketing of Arasena-A |
| Hismanal®; Fetal Monitors and the Telemetry System; Sonovista-Color; Sonovista-ET |
| 1996 |
Signed agreements with Norian Corporation for the development and marketing in Japan of Norian SRS®; and with Dainippon Pharmaceutical Co.,Ltd., for the co-marketing of Epadel in Japan |
| Commenced JELIS (EBM study for Epadel) |
| 1997 |
Concluded distribution agreement with Ajinomoto Co.,Inc., for Atelec® (calcium channel antagonist) |
| Atelec® ; Bilmeter-E; DXA-70; Gonastick; Superthermo |
| 1998 |
Comarketed Dainippon Pharmaceutical's Cetapril® (ACE inhibitor) |
| Osteomark® ; Amtec; Sonovista-Color II; Medilaser Soft 1000 |
| 1999 |
Naoyuki Mochida appointed president |
| Additional indications for IFN α (for CML) and IFN β (for SSPE) approved; concluded distribution agreement with Janssen Kyowa Co.,Ltd., for Ortho® 777-28/M-21; licenesed a patent of Fas/FasL (for genetherapy) to Novartis |
| Licensed a patent Fas/FasL (for screening) to Bristol Myers Squibb |
| Epadel S 300 and 600; Video Hysteroscope; Hysterofiberscope; Collage Furfur; Miotecter® |
 |
| 2000 |
Signed agreements with Riken for co-research in structual genomics |
| TV probe III; Skina Babe Series (renewal); AuDX |
| 2001 |
Signed agreements with 3M for the development and marketing of Aldara; with Maruishi Pharmaceutical Co.,Ltd. for the co-development and co-marketing of capsaicin |
| Arasena-A 3% cream; Gonastick 25; Collage Essence |
| 2002 |
Signed agreements with Aventis Pharma Ltd. for the distribution and co-promotion of Suprecur®; with Lundbeck A/S for the co-development and co-marketing of escitalopram
Established Neutrapharmaceutical business |
| Spurecur®; Medilaser-RF; Sonovista-ColorFD |
| Obtained the certification of ISO 14001 for Otawara Plant |
| 2003 |
Signed agreements with Novo Nordisk for the distribution of Novo-Heparin; with Medix Biochemica Oy and Unitika Ltd. for the distribution of a diagnostic test kit for acute pancreatitis |
| Started operation of Mochida Medical Systems Co.,Ltd. |
Thrombin Mochida Soft bottle; FM2; ABaer Cub; Collage S series;
and a masticatory supplement |
| 2004 |
Started operation of Mochida Healthcare Co.,Ltd. |
| Started operation of Mochida Siemens Medical Systems Co.,Ltd. |
| Epadel S 900; Sonovista-C3000 |
| 2005 |
Started operation of Mochida Pharmaceutical Plant Co.,Ltd. |
| Sonovista G40; Sonovista G60 S; Collage Furfur Liquid Soap; Collage Furfur S |
| 2006 |
Sonovista G60 S; Medilaser Soft Pulse 10; Sonovista X500; Sonovista X300; Acuson X300 |
| 2007 |
Signed agreements with JCR Pharmaceuticals Co., Ltd. for co-development and commercialization of a stem cell drug; with Novartis Pharma K.K. for the co-promotion of Diovan®; and with United Therapeutics Corporation for the distribution of Remodulin®. |
| Beselna Cream 5% |
 |
| 2008 |
Signed a license agreement with Wyeth Pharmaceuticals for TRPV1 receptor antagonists. |
| Dinagest; Collage White Peel |
| 2009 |
Collage Furfur Next |
